



Panacea Biotec
Innovation in support of life

3rd January, 2017

The Manager, Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec Ensures Increased availability of Life Saving Drug Cilamin 250 (D-Penicillamine IP 250mg) Capsules for Treatment of Wilson's disease in India

Dear Sir,

The Company is pleased to announce the increased availability of Life Saving Drug Cilamin 250 (D-Penicillamine IP 250mg) Capsules used for treatment of Wilson's disease, Rheumatoid Arthritis and other conditions. These capsules witnessed short supply in the market during last few months due to non-availability of raw material, i.e. D-Penicillamine, in India.

A copy of the Press Release titled "Panacea Biotec Ensures Increased availability of Life Saving Drug Cilamin 250 (D-Penicillamine IP 250mg) Capsules for Treatment of Wilson's disease in India" being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you,
Sincerely yours,
for **Panacea Biotec Ltd.**


Vinod Goel

**Group CFO and Head Legal
& Company Secretary**

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Press Release:

For Immediate Distribution

Panacea Biotec Ensures Increased availability of Life Saving Drug Cilamin250 (D-Penicillamine IP 250mg) Capsules for Treatment of Wilson's disease in India

New Delhi, 03rd January 2017: Cilamin 250 Capsule used for treatment of Wilsons disease, Rheumatoid Arthritis and other conditions witnessed short supply in the market during the last few months due to non-availability of raw material D-Penicillamine in India.

Panacea Biotec, India's leading Biotechnology Company is pleased to inform all Doctors, Patients and Families that production for our brand Cilamin 250 Capsules has increased due to the receipt of additional quantity of raw material. We now have improved supply of Cilamin250 capsule which has been made available in the retail market.



Panacea Biotec had already released limited quantities on 9th of December 2016 to select stockiest all over India. Additional quantity has now been made available starting from 2nd January 2017 at different stockiest all over India.

We are in regular touch with Department of Pharmaceuticals, NPPA and Drug Controller General of India for facilitating regular supplies of Cilamin250 capsules in the market.

All patients are advised to register themselves on www.cilamin.com for regular updates on availability of this life saving drug.

We regret the inconvenience caused to Patients, Families, Doctors and all other stakeholders due to this temporary shortage.

Notes to the Editors



Contd.2

B-1 Ext./A-27, MCIE, Mathura Road, New Delhi-110044; Email: pdkaran@panaceabiotec.com Tel: DID: +91 41578080, +91 41679000 Ext. 1406, Mobile: +91 9312693040; Fax: +91 41578002, Web: www.panaceabiotec.com CIN: L33117PB1984PLC022350

About Panacea Biotec

Panacea Biotec is one of India's leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 3 biotechnology companies (Biospectrum – ABLE Survey, July 2014) and the top 50 pharmaceutical companies (AIOCD AWACS – MAT May 2016) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of Oncology, Organ Transplantation, Nephrology, Diabetes, Osteoporosis, and Pediatric Immunization Vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro particles, liposomes, gastro-retentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. Panacea Biotec has research collaborations with leading national and international research organizations and corporations. Panacea Biotec's state of the art manufacturing facilities for Vaccines and Pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2700 employees including around 125 scientists working across 4 R&D centers of the company.

For more information, please contact –



Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com



B-1 Ext./A-27, MCIE, Mathura Road, New Delhi-110044; Email: pdkaran@panaceabiotec.com Tel: DID: +91 41578080, +91 41679000 Ext. 1406, Mobile: +91 9312693040; Fax: +91 41578002, Web: www.panaceabiotec.com CIN: L33117PB1984PLC022350